156
Participants
Start Date
March 27, 2023
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
ATG-022
"Dose Escalation Phase:~A treatment cycle of ATG-022 will be defined as 21 days. Dosing will begin at 0.3 mg/kg once every 3 weeks (Q3W) with 1 subject ,the following dose cohorts (0.9, 1.8, 2.4, 3.0, and 3.6 mg/kg Q3W) will require at least 3 and up to 6 evaluable subjects by using dose escalation plan of 3+3 design."
COMPLETED
Cancer Research SA Pty Ltd, Adelaide
RECRUITING
Cabrini Health Limited, Malvern
RECRUITING
Integrated Clinical Oncology Network Pty Ltd (Icon), South Brisbane
RECRUITING
West China Hospital, Sichuan University, Chengdu
RECRUITING
Fujian Cancer Hospital, Fuzhou
RECRUITING
Jinan Central Hospital, Jinan
RECRUITING
Gansu provincial cancer hospital [recruiting], Lanzhou
RECRUITING
The Affiliated Hospital of Qingdao University, Qingdao
RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
RECRUITING
Tongren Hospital Shanghai, Shanghai
RECRUITING
Liaoning Cancer Hospital, Shenyang
RECRUITING
The Fourth Hospital of Hebei Medical University, Shijiangzhuang
RECRUITING
Shanxi provincial cancer hospital, Taiyuan
RECRUITING
Hubei Cancer Hospital, Wuhan
RECRUITING
The First affiliated hospital of Xi'An Jiao Tong Ubiversity, Xi'an
RECRUITING
Xuzhou Central Hospital, Xuzhou
Antengene Biologics Limited
INDUSTRY